Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naive Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Anti-hyperglycaemic Drugs With a 6-month Safety Extension Period

Trial Profile

6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naive Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Anti-hyperglycaemic Drugs With a 6-month Safety Extension Period

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms EDITION-III
  • Sponsors Sanofi
  • Most Recent Events

    • 25 Sep 2020 Results from real-world studies ACHIEVE, REACH, REGAIN, and RCTs EDITION 1-3 and BRIGHT assessing Treatment satisfaction in people with type 2 diabetes receiving basal insulin, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
    • 25 Sep 2020 Results of pooled analysis from NCT02855684; NCT01689142 and NCT01676220 assessing efficacy and safety of Gla-300 in East Asian population with type 2 diabetes, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
    • 11 Jun 2019 Results reporting data on patient satisfaction from EDITION 3 and BRIGHT trial presented at the 79th Annual Scientific Sessions of the American Diabetes Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top